reference/21589567

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21589567

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial
endingPage	994
issn	1347-9032 1349-7006
issueIdentifier	5
pageRange	987-994
publicationName	Cancer Science
startingPage	987
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5ff2e10f52001ce2491744a2d3b59295
bibliographicCitation	Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y. Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer. Cancer Science. 2017 May;108(5):987–94. doi: 10.1111/cas.13221.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce3e560bb7bd2f92a52de58cf400eef7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f209744d251c5878f8530070a8a88975 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d4aaafdb5a58a674008115215680bf5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0fe9af1d9a10255a35de56f599222ff3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efbdae5f3a31bd165270df27f43f8bdd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e717c369c2a4ea2b1c7d4aa11c35a4dd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d6537d01e48ffda034c7c51e9e0e85d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a1efe8d3e124424cd16421f0541bdf3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9226-895X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5b30c68c67de4c064dbd4b47e0b0e4e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3147c8ae15ece1da1de173e614e1a73 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f6a7812a04c986b0aea9d697b911013 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3dd0bd284d5b2b2b9341505b8170e72 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c221805f175e8d3b6eec1b6f7e3150aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42697f570925a82446abf6dabc02b613 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef63e8fe378c0e032633b59c088f4525 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_af522f7ef768729bc0ce4b24f57a03cc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc8a9e73c0591c0f3806cb8a16da48a3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f53a29f9718b0eb49841fcdf6f13f7a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_94510e40937d95ba096d7af37778fb65 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2686-8732 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8160a05b4b709ba7a067f2bdea608938 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_84dac1709c5473d0497ce3268cf0a237 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3514-9927
date	201705
identifier	https://doi.org/10.1111/cas.13221 https://pubmed.ncbi.nlm.nih.gov/28256066 https://pubmed.ncbi.nlm.nih.gov/PMC5448660
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30320 https://portal.issn.org/resource/ISSN/1347-9032 https://portal.issn.org/resource/ISSN/1349-7006
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer
discusses	http://id.nlm.nih.gov/mesh/M0026156 http://id.nlm.nih.gov/mesh/M0495206 http://id.nlm.nih.gov/mesh/M0000629 http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0510426 http://id.nlm.nih.gov/mesh/M0184558
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D017239Q000008 http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D018719Q000378 http://id.nlm.nih.gov/mesh/D000418Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D044466 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D043823Q000008 http://id.nlm.nih.gov/mesh/D000077143 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000971Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D016896
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9d7fe60f25abdf582afc7cdca238bde8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_73717aafac1e7701dab0fa02b8936926 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8658 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7ed75134b36b0e173fb44798462e4e66 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603

Showing number of triples: 1 to 79 of 79.